Tom Benson is the founder and CEO of Mitrix Bio, a Pleasanton, California biotech building toward whole-body mitochondrial transplantation. A serial software, hardware, and science entrepreneur, he managed the Linac Coherent Light Source femtosecond X-ray laser at Stanford's SLAC before turning his attention to the cell's power plants. His pitch is audacious and specific: grow young mitochondria from a person's own stem cells in a bioreactor, then transfuse them back to restore cellular energy and push the human lifespan toward 130 years.
HebeCell Corp is a Natick, Massachusetts biotech developing allogeneic, off-the-shelf cell therapies grown from induced pluripotent stem cells (iPSCs). Its core invention is a suspension-bioreactor platform, ProtoNK, that produces natural killer (NK) cells indefinitely and at scale - a manufacturing approach the company says no other lab can match. Founded in 2016, HebeCell aims to make cancer and degenerative-disease therapies cheaper, safer, and available without a matched donor, under the tagline 'Incurable no more.'
Stämm is a deep-tech biomanufacturing company building a desktop-scale, 3D-printed, bubble-free bioprocessor that replaces the giant stainless-steel tanks of conventional pharma. Founded in Buenos Aires and headquartered in San Francisco, the company is pursuing a vision of decentralized, AI-driven production of biologics and cell therapies.
Justin Kolbeck is Co-Founder and CEO of Wildtype, the San Francisco-based cultivated seafood company that became the first to receive FDA regulatory clearance for cell-grown salmon in the United States. A former U.S. Foreign Service Officer who served in Pakistan and Afghanistan, Kolbeck channeled his firsthand experience with global food insecurity into co-founding Wildtype in 2016 alongside cardiologist and microbiologist Aryé Elfenbein. The company has raised over $123 million in funding - including a record $100 million Series B backed by Leonardo DiCaprio, Jeff Bezos, and Robert Downey Jr. - and launched its sushi-grade coho salmon at award-winning restaurants in 2025. Wildtype's salmon, grown in stainless steel bioreactors in a converted San Francisco brewery, was named one of TIME's Best Inventions of 2025.
Yuyo Llamazares Vegh is the CEO and Co-Founder of Stämm, a San Francisco-based biotech company reinventing biomanufacturing through miniaturized 3D-printed microfluidic bioreactors. A native of Argentina with a background in agricultural engineering and bioprocesses from the University of Buenos Aires, Yuyo co-founded Stämm in 2016 alongside his cousin Federico D'Alvia Vegh after spotting a fundamental gap between biology's potential and the outdated tools available to harness it. Stämm's platform - desktop-sized, modular, and scalable - is designed to make the production of biologics, cell therapies, and gene therapies accessible and repeatable at any scale. The company has raised over $17 million including a Series A led by Varana Capital with participation from Draper Associates and SOSV's IndieBio, and has attracted former Merck KGaA CEO Stefan Oschmann to its board. Yuyo was selected as an Endeavor Entrepreneur in 2023.
Wildtype is a San Francisco-based cultivated seafood company that grows real salmon from fish cells in stainless steel bioreactors - no fishing, no farming, no ocean required. Founded in 2016 by a cardiologist-turned-food-scientist and a former U.S. Foreign Service officer, the company received FDA clearance in May 2025, making it the first cultivated seafood product approved for sale in the United States. With $123.5M raised and backing from Jeff Bezos, Leonardo DiCaprio, and Cargill, Wildtype is betting that the future of seafood is grown, not caught.